Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-755 in Congenital Thrombotic Thrombocytopenic Purpura
NCT03393975Phase 3Completed
- Sponsor
- Takeda
- Start
- Oct 2017
- Primary completion
- Dec 2023
- Countries
- 9
01
Overview
A Phase 3 trial of Apadamtase alfa in congenital thrombotic thrombocytopenic purpura (cTTP), sponsored by Takeda. Started Oct 2017; status: completed.
02
Drugs
Apadamtase alfa
03
Conditions
congenital thrombotic thrombocytopenic purpura (cTTP)
Beyond the preview
Go deeper on NCT03393975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03393975.